Papers/PMID:33710626
Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates.
The Cochrane database of systematic reviews2021The record
2 findings · 1 compound · 2 endpoints · 2 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
2 findings
Zn(2+) — no detected effect on retinopathy of prematurity incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Enteral zinc supplementation may have little or no effect on common morbidities such as bronchopulmonary dysplasia (RR 0.66, 95% CI 0.31 to 1.40, 1 study, 193 infants; low-certainty evidence), retinopathy of prematurity (RR 0.14, 95% CI 0.01 to 2.70, 1 study, 193 infants; low-certainty evidence), bacterial sepsis (RR 1.11, 95% CI 0.60 to 2.04, 2 studies, 293 infants; moderate-certainty evidence), or necrotising enterocolitis (RR 0.08, 95% CI 0.00 to 1.33, 1 study, 193 infants; low-certainty evidence).”
Quoted verbatim from Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates.. - Study
- meta-analysis
- Participants
- 193
- Population
- Hospitalised preterm infants given enteral zinc versus placebo or no supplementation; single study
Effect 0.14 risk ratio, 95% CI 0.01 to 2.7
Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates.2021PMID:33710626Permalink
Zn(2+) — no detected effect on necrotising enterocolitis incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Enteral zinc supplementation may have little or no effect on common morbidities such as bronchopulmonary dysplasia (RR 0.66, 95% CI 0.31 to 1.40, 1 study, 193 infants; low-certainty evidence), retinopathy of prematurity (RR 0.14, 95% CI 0.01 to 2.70, 1 study, 193 infants; low-certainty evidence), bacterial sepsis (RR 1.11, 95% CI 0.60 to 2.04, 2 studies, 293 infants; moderate-certainty evidence), or necrotising enterocolitis (RR 0.08, 95% CI 0.00 to 1.33, 1 study, 193 infants; low-certainty evidence).”
Quoted verbatim from Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates.. - Study
- meta-analysis
- Participants
- 193
- Population
- Hospitalised preterm infants given enteral zinc versus placebo or no supplementation; single study
Effect 0.08 risk ratio, 95% CI 0 to 1.33
Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates.2021PMID:33710626Permalink